Table 3.

Clinical trials related to molecular components of pre-metastatic niche formation

Molecular type	Title	Disease or conditions	Interventions	Phase	Trial number
EGF	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Colorectal Cancer	Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine	Early Phase 1	NCT06011772
	EMB-01 in Patients With Advanced/ Metastatic Gastrointestinal Cancers	Metastatic Gastrointestinal Carcinoid Tumor	EMB-01	Phase 1/2	NCT05176665
FGF	Fulvestrant Plus Anlotinib in HR( + )/ HER2(-) Metastatic Breast Cancer With FGFR Mutation	Breast Cancer	Fulvestrant plus Anlotinib	Phase 2	NCT04936295
	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)	Metastatic Cholangiocarcinoma	TYR200	Phase 1	NCT06160752
	Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma	Gastric Cancer	Infigratinib	Phase 2	NCT06206278
VEGF	A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	Clinical Stage III Cutaneous Melanoma AJCC	Atezolizumab, Bevacizumab	Phase 2	NCT04356729
HGF	Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	Squamous Cell Carcinoma of the Head and Neck	Ficlatuzumab, Cetuximab	Phase 1	NCT02277197
	To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients	Colorectal Cancer Metastatic	YYB101	Phase 1/2	NCT04368507
Extracellular Vesicles	Characterization of Extracellular Vesicles in Breast Cancer Patients	Breast Cancer	Blood sample	Observa-tional	NCT05798338
	Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients (ExoColon)	Colorectal Cancer	Diagnostic test	Observa-tional	NCT04523389